Immunomodulatory effects of anti-angiogenic drugs (Q37847051)

24 August 2017

1 reference

title

Immunomodulatory effects of anti-angiogenic drugs (English)

1 reference

24 August 2017

main subject

angiogenesis inhibitor

1 reference

A Heine

1

1 reference

24 August 2017

S A E Held

2

1 reference

24 August 2017

A Bringmann

3

1 reference

24 August 2017

T A W Holderried

4

1 reference

24 August 2017

P Brossart

5

1 reference

24 August 2017

publication date

25 February 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

25

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

899-905

1 reference

The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

VEGF blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Effects of imatinib on normal hematopoiesis and immune activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Profound inhibition of antigen-specific T-cell effector functions by dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Effects of nilotinib on regulatory T cells: the dose matters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Proteasome inhibitors: antitumor effects and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

The proteasome: a suitable antineoplastic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Identification and validation of novel therapeutic targets for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

The proteasome inhibitor bortezomib enhances the susceptibility to viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Proteasome inhibition activates the mitochondrial pathway of apoptosis in human CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Proteasome inhibition suppresses essential immune functions of human CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

Targeting tyrosine kinases in cancer: the second wave

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

7 January 2021

Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

7 January 2021

Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

7 January 2021

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.24

7 January 2021

Identifiers

DOI

10.1038/LEU.2011.24

1 reference

Dimensions Publication ID

24 August 2017

1019283501

0 references

1 reference